Our pipeline includes clinical compound inhibitors (repurposed drugs) to be rapidly progressed into clinical trials in Triple Negative Breast Cancer and Chronic Heart Failure as oral drugs, and pre-clinical compound inhibitors to be developed as a high potency injectable drugs